Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1/PHASE2
45 participants
INTERVENTIONAL
2022-03-14
2024-02-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multi OIT to Test Immune Markers After Minimum Maintenance Dose
NCT03181009
Oral Immunotherapy for Childhood Egg Allergy
NCT00461097
Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy
NCT01846208
Oral Immunotherapy for Wheat Allergy
NCT01980992
Treatment of Egg Allergy in Children Through Oral Desensitization (EGG OIT)
NCT00597558
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment Options 1, 2, 3, 4, 5
Participants will fall into 1 of 5 treatment options dependent on the treatment received (ADP101 or placebo) during the parent study and their tolerance of the treatment regimen during the parent study.
ADP101
Active dry powder formulation at various volumes.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ADP101
Active dry powder formulation at various volumes.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Hypersensitivity to epinephrine or any of the excipients in ADP101
* Prior or concurrent therapies as follows:
* beta-blockers, ACE inhibitors, ARBs or calcium channel blockers
* regular steroid medication use
* therapeutic antibody treatment currently or within the previous 6 months
* any food immunotherapy currently or within the previous 12 weeks, except ADP101
* investigational agents other than ADP101
* in the build up phase of non-food immunotherapy
* Any other condition that might preclude safe participation in the study
4 Years
57 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alladapt Immunotherapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mei-Lun Wang, MD
Role: STUDY_DIRECTOR
VP of Clinical Development, Alladapt Immunotherapeutics, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Study Site
Mission Viejo, California, United States
Study Site
Rolling Hills Estates, California, United States
Study Site
San Diego, California, United States
Study Site
Colorado Springs, Colorado, United States
Study Site
Denver, Colorado, United States
Study Site
Tampa, Florida, United States
Study Site
Atlanta, Georgia, United States
Study Site
Marietta, Georgia, United States
Study Site
Normal, Illinois, United States
Study Site
Ann Arbor, Michigan, United States
Study Site
Chapel Hill, North Carolina, United States
Study Site
Cincinnati, Ohio, United States
Study Site
Charleston, South Carolina, United States
Study Site
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ADP101-MA-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.